Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-OLE open-label long-term extension of fitusiran in hemophilia A or B
MOH_2019-06-16_007203Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Mar 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fitusiran in hemophilia A and hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Long-term safety and tolerability of fitusiran. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on MOH_2019-06-16_007203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-16_007203.